The Association for Molecular Pathology (AMP) released draft guidelines for interpreting and reporting cancer sequencing variants, covering biomarkers that predict therapy response or resistance, liquid biopsy reporting, and mutational signatures such as TMB, MSI and HRD. The draft adds recommended language and reporting frameworks aimed at harmonizing variant interpretation across clinical labs and sequencing platforms. AMP solicits community feedback and emphasizes updates are intended to reduce reporting variability and better align genomic reports with treatment decision‑making.